Watson Signs License Agreement With GeneraMedix
For exclusive US marketing rights to a generic version of Ferrlecit
Watson has signed a licensing agreement with GeneraMedix for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection). The drug is indicated for the treatment of iron deficiency anemia in hemodialysis patients receiving supplemental epoetin therapy.
GeneraMedix has filed an Abbreviated New Drug Application (ANDA) with the FDA for a sodium ferric gluconate complex in sucrose product, that is packaged in a vial.
Under the terms of the agreement, GeneraMedix will supply the product to Watson to market, sell and distribute it in the US.
New Jersey-based GeneraMedix is a pharmaceutical company that develops, markets and distributes generic injectable products.
Headquartered in California, Watson Pharmaceuticals develops, manufactures, markets and distributes brand and generic pharmaceutical products.
Related Insight
Suppliers Directory
Arco Information - Connecting Data
Arco Information was first established in 1991. Its registered office is located in Mechelen, Belgium. Arco Information develops, sells and implements software products in the domain of document management, electronic archiving, workflow management, mail management and storage.
Suppliers
Centrical Global Limited - Global Clinical Trial Feasibility
Centrical specialises in comprehensive, streamlined, industry-leading global clinical trial feasibility for pharmaceutical and biotechnology companies.
Suppliers
Cancer Research Technology (CRT) - Advancing Discoveries to Beat Cancer
Cancer Research Technology Ltd (CRT) is the cancer-focused technology development and commercialisation arm of Cancer Research UK, the world's largest cancer charity.
Suppliers
VITLAB® - Competence in Labware
VITLAB® is a leading manufacturer of liquid handling equipment and plastic laboratory products and has distinguished itself as a specialist in the development and manufacture of high quality laboratory products made of a wide variety of plastics. Whether volume measuring, titration, dosing, pipetting, or saving and storing: The goal of our development is the creation of products which facilitate your daily lab tasks and deliver perfect results.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Reversed-Phase Analysis of Alkylbenzene Sulfonates
Published by Tosoh Bioscience
White Papers
The SensaSlim Solution
Published by SensaSlim
White Papers
Medical Image Interpretation & Assessment
Published by CoreLab Partners
White Papers
Crystal Characterization of Almatis Tabular Alumina
Published by Phenom World
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.